Jailani, Nurhima .

HRN: 21-82-14  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/18/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
08/18/2022
08/25/2022
IV
160 Mg
Q8H
Amoebiasis
Waiting Final Action 
08/18/2022
CEFTRIAXONE 1G (VIAL)
08/18/2022
08/25/2022
IV
1500mg
Q24H
PCAP
Waiting Final Action 
08/19/2022
MEBENDAZOLE 50MG/ML, 60ML SUSPENSION (BOT)
08/19/2022
08/22/2022
PO
2ml
Q12
T. Tricura Infection, E.vermicularis Infection
Waiting Final Action 
08/22/2022
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
08/22/2022
08/29/2022
IVTT
550mg
Q8
Infectious Gastroenteritis
Waiting Final Action 
08/25/2022
MEBENDAZOLE 50MG/ML, 60ML SUSPENSION (BOT)
08/25/2022
08/25/2022
PO
25ml
1 Dose
Ascariasis
08/25/2022
MEBENDAZOLE 50MG/ML, 60ML SUSPENSION (BOT)
08/25/2022
08/27/2022
PO
5ml
BID
Ascariasis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: